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Curcumin bioconjugates, viz. di-O-tryptophanylphenylalanine curcumin (2), di-O-decanoyl curcumin (3),
di-O-pamitoyl curcumin (4), di-O-bis-(g,g)folyl curcumin (6), C4-ethyl-O-g-folyl curcumin (8) and
4-O-ethyl-O-g-folyl curcumin (10) have been synthesized and tested for their antibacterial and antiviral
activities. The conjugates 2, 3, 4, 6 and 8 have shown very promising antibacterial activity with MIC
ranging between 0.09 and 0.67 mM against Gram-positive cocci and Gram-negative bacilli. Further, the
conjugates 2, 3, 6, 8 and 10 have been screened for their antiviral activities against HSV, VSV, FIPV, PIV-3,
RSV and FHV and the molecules 2 and 3 have shown good results with EC50 0.011 mM and 0.029 mM
against VSV and FIPV/FHV, respectively. However, the molecules did not show expected results against
HIV-1 IIIB and ROD strains in MTT assay.
 2009 Elsevier Masson SAS. All rights reserved.1. Introduction
Curcumin, 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-
3,5-dione, commonly known as diferuloyl methane, is a natural
yellow pigment derived from rhizomes of the plant Curcuma longa
(Zingiberaceae) – a plant grown in tropical southeast Asian and
Indian subcontinent, and has been proved as potent antioxidant,
anti-inflammatory, antiviral and anticancer agent through modula-
tion of multiple cellular machinery [1–6]. Turmeric, a spice used to
provide specific flavor and yellow color to curry, has been used for
many centuries as an Indian folklore medicine in Ayurveda – an
ancient traditional systemofmedicine for treatment ofwide range of
illnesses. Current traditional Indian medicine uses it for biliary
disorders, anorexia, cough, diabetic wounds, hepatic disorder,
rheumatism, blood purification and rheumatoid arthritis [7–9].
Recent studies have shown curcumin as a potential molecule in the
treatment of different forms of cancer, e.g., cervical cancer caused by
HPV [10–12].
It has been observed that both curcumin and the oil fraction,
suppress the growth of several bacteria like Streptococcus, Staphy-
lococcus, Lactobacillus, etc [12,13] and human pathogenic fungi.5.
ingh).
son SAS. All rights reserved.Turmeric oil is also active against Aspergillus flavus, Aspergillus
parasiticus, Fusarium moniliforme and Penicilium digitatum [14,15].
Results have shown that curcumin treatment effectively
reduced Coxsackie Virus B3 replication through desregulation of
Ubiquitin–Proteosome System (UPS) and COP9 Signalosome (CSN)
performing a critical role in their life cycle, i.e., it strongly reduced
viral RNA expression and further protein synthesis [16,17]. Curcu-
min has been identified as inhibitor of HIV-1 LTR directed gene
expression and viral replication. A previous study has shown that
curcumin, a pharmacologically safe compound, is able to block HIV
replication by inhibiting HIV-integrase and protease [18,19].
The double bonds in curcumin provide definite conformational
flexibility to the molecule, which accounts for its various
properties. Further, blocking of phenolic groups decreases its
antioxidant activity since these groups play critical role in enzy-
matic activity at receptor sites [20,21]. Studies have revealed that
curcumin has very low bioavailability due to its poor absorption
and rapid metabolism in the liver and intestinal wall [22,23].
Curcumin is highly hydrophobic and cannot be administered
systemically. On intravenous administration, it disappears rapidly
from the blood and quickly appears as metabolites in the bile
[10,24,25]. Therefore, one of the most appreciable approaches is
to make biodegradable conjugates of curcumin molecule with
suitable ligands to enhance its cellular uptake. For preparing
bioconjugate of curcumin, amino acids and fatty acids – natural
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synthesis of thymidine and other nucleotides, were selected [26–
29]. These bioconjugates are supposed to enhance cellular uptake,
lipophilicity of the molecule and sustained release of drug
molecule to improve the half-life and reduce the rate of metab-
olism of curcumin molecule inside the cell.
We have previously reported a series of nucleosidic molecules
[30–33] of significant therapeutic applications. In the present
pursuance, we are focusing on naturally occurring molecules –
curcumin and its bioconjugates, e.g., di-O-tryptophanylphenylala-
nine curcumin (2), di-O-decanoyl curcumin (3), di-O-pamitoyl
curcumin (4), di-O-bis-(g,g)folyl curcumin (6), C4-ethyl-O-g-folyl
curcumin (8) and 4-O-ethyl-O-g-folyl curcumin (10). These bio-
conjugates have been screened for their antibacterial and antiviral
activities.
2. Chemistry
Curcumin, 1, has two phenolic groups and one active methylene
group which can be utilized as potential sites for chemical varia-
tions and covalent linkage with biomolecules. We have synthesizedHN
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Scheme 1. Synthesis of curcumin bioconjugates with dcurcumin bioconjugates 2, 3, 4, 6, 8 and 10, wherein the phenolic
hydroxyls and active methylene group on curcumin have been
utilized.
For the synthesis of compound 2 (Scheme 1), curcumin 1 was
reacted with t-boc–N-trp–phe–COOH (indigenously synthesized)
in 1:2 molar proportion using dicyclohexylcarbodiimide (DCC)
coupling procedure in the presence of DMAP in anhydrous
dichloromethane (DCM) to yield di-O-tryptophanylphenylalanine
curcumin 2 in 53% yield [34].
Further, curcumin was reacted with decanoyl chloride and pal-
mitoyl chloride in 1:2 molar proportion in the presence of DMAP in
anhydrous pyridine to get the molecules 3 and 4 (Scheme 1) in 56%
and 44% yield, respectively [35].
For the syntheses of conjugates 6, 8 and 10, folic acid was acti-
vated to p-nitrophenyl folate 5 (FA-PNP) (Scheme 2) using p-
nitrophenol in the presence of DCC in pyridine and triethylamine
(TEA). The completion of the reactionwas assessed by precipitation
of dicyclohexylurea (DCU) [36].
The activated folate 5was reacted with curcumin 1 in 2:1 molar
proportion in the presence of DCC and DMAP to get the compound
6 (Scheme 3) in 48% yield.O O
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cumin were protected using benzoyl chloride. This di-O-benzoyl
curcumin was conferred on a carbanionic character at the active
methylene site by using a strong base, like NaOEt and reacted with
2-chloroethanol – a linker unit, followed by reaction with activated
folate 5 in 1:1 molar proportion, using DCC and DMAP to yield the
compound 8 in 45% yield (Scheme 3).
The compound 10 was synthesized using only one phenolic
group on curcumin molecule. Curcumin was taken up in 5%
aqueous NaOH and reacted with 2-chloroethanol as linker unit. The
resulting product, dissolved in anhydrous pyridine, was added
dropwise to the activated folate 5 in 1:1 molar proportion in the
presence of DCC and DMAP to yield the compound 10 in 26%
(Scheme 4).
All the newly synthesized bioconjugates were characterized by
UV, 1H NMR, 13C NMR, mass spectra and elemental analyses. The
molecules 2, 3, 4, 6 and 8 have been screened for their antibacterialO
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Scheme 3. Synthesis of curcumin bioconjugates at activactivities against gram-positive cocci and gram-negative bacilli and
the molecules 2, 3, 6, 8 and 10 for their antiviral activities against
a range of viruses using standard protocols.3. Results and discussion
3.1. Antibacterial activity
The molecules 2, 3, 4, 6 and 8 have shown remarkable anti-
bacterial activities with MIC ranging between 0.09 and 0.67 mM (in
vitro) against gram-positive cocci (Streptococcus virudans) as well as
gram-negative bacilli (Escherichia coli, Klebsiella pneumoniae,
Proteus mirabeilis) bacterial strains. Results are given in Table 1.
The most encouraging results were found against Streptococcus
viridans, E. coli, K. pneumoniae and P. mirabeilis with molecules 6
and 8 having MIC 0.27 mM (0.54 mM against P. mirabeilis) and
0.09 mM, respectively, for each bacterial strain. The molecules 2, 3
and 4 have shown highly satisfactory results as antibacterials with
MIC 0.43, 0.369 and 0.591 mM, respectively, against E. coli and K.
pneumoniae (curcumin shows MIC value 1.23–2.47 mM). These
results were compared with known antibiotics as standards as
shown in Table 1. The antibacterial activity of the bioconjugates was
3.7–27 times higher than that of curcumin itself. The better results
obtained with these bioconjugates may be because of their struc-
tural similarity with the bacterial cell wall that possesses amino
acids and lipids as its integral part and folic acid is a requirement as
a cofactor in the synthesis of thymidine and other nucleotides. This
ensured high cellular uptake and thus enhanced bioavailability
[26–29].
The ester bonds in these molecules are biodegradable, i.e., they
get hydrolysed by carboesterases present in the cells and this
results in the enhanced effective concentration of the drug at the
target site and sustained release of curcumin further ensures low
toxicity, if any.O
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The molecules 2, 3, 6, 8 and 10 were examined for their cyto-
toxicity and antiviral activity against a variety of DNA and RNA
viruses using different cell cultures. The results have been shown in
Table 2. The compound 2 has shown good result against vesicular
stomatitis virus and compound 3 against feline corona and feline
herpes viruses. The EC50 value (0.011 mM) of compound 2 was
almost nine times lower than its CC50 value (0.096 mM). Similarly,
the EC50 (0.029 mM) values of compound 3 against feline corona
and feline herpes viruses were almost five times lower than its CC50
(0.146 mM) value. The EC50 (0.029 mM) of compound 3 has been
observed as almost ten times better than that of curcumin
(0.271 mM) against FIPV and FHV. Further, the CC50 values of these
bioconjugates weremuch higher than that of curcumin. Thus, these
results confirmed the better acceptability of curcumin bio-
conjugates by the cells under study than curcumin itself. All these
compounds were also tested against Influenza A H1N1/H3N2
subtype and Influenza B in MDCK cell lines. However, none of the
test compounds was able to inhibit cytopathic effects of Influenza A
or B virus at subtoxic concentrations or the highest concentration
tested (100 mg/ml).Table 1
Antibacterial activities of curcumin and its conjugates 2, 3, 4, 6 and 8 against
Gram-positive and Gram-negative bacterial strains.
Compound MIC(mM)a
Gram-positive Gram-negative
S. viridans E. coli K. pneumoniae P. miraleilis
2 0.43 0.43 0.43 0.43
3 0.67 0.33 0.67 0.67
4 0.53 0.53 0.53 0.53
6 0.27 0.27 0.27 0.54
8 0.09 0.09 0.09 0.09
Curcumin 2.47 1.23 1.23 1.23
Ampicillin trihydrate >2.47 1.23 0.60 1.23
Gentamycin sulfate >1.73 >1.73 >1.73 >1.73
a MIC (mM)¼Minimum inhibitory concentration, i.e., the concentration in the
tube with highest dilution showing no turbidity.The positive results with compounds 2 and 3 might be due to
their higher lipophilicity, which enhances their cellular uptake. The
lipophilicities of compounds 2 and 3 are expressed by log P values
determined experimentally (Table 3) using the standard stir-shake
flaskmethod in an octanol–water system [37]. These values are also
compared with values obtained by a computer programme –
Molinspiration method. The log P values of the compounds 2 and 3
were higher than that of curcumin. As expected, the lipophilicity of
the compound 3 was much higher than that of the compound 2.
This reaffirmed that the bioconjugates have better biocompatibility
whenwe are concerned about bioavailability of curcuminmolecule.
Since ester bonds are biodegradable by carboesterases, these
molecules ensure higher and sustained bioavailability.
The compound 6which did not show positive result against the
viruses under study has been found to be very active against HPV
causing cervical cancer in Indian women [Singh et al. unpublished
results]. The bioconjugates, however, did not show any activity
against HIV-1 (IIIB and ROD strains) as shown in Table 4.
4. Conclusion
We have prepared a number of curcumin bioconjugates bearing
covalent linkage with suitable ligands, viz. dipeptide, fatty acids
and folic acid to enhance cellular uptake of curcumin [26–29].
These bioconjugates were screened for their antibacterial activity
against gram-positive and gram-negative bacteria using micro-
dilution broth susceptibility test method [38].
The molecules 2, 3, 4, 6 and 8 have shown much better anti-
bacterial activities with MIC ranging between 0.09 and 0.67 mM
than curcumin (MIC value 1.23–2.47 mM).
Further, the bioconjugate 2 has shown good antiviral property
with EC50 0.011 mM against vesicular stomatitis virus and similarly,
the bioconjugate 3 with EC50 0.029 mM against feline corona and
feline herpes viruses. The EC50 values are five to ten times lower
than their CC50 values.
The bioconjugates 2, 3, 6, 8 and 10 were also screened against
HSV, coxsackie virus B4, respiratory syncytial virus, parainfluenza
virus, reovirus-1, punta toro virus, vaccinia virus and HIV-1 (IIIB and
Table 2
Cytotoxicities and anrtiviral activities of curcumin conjugates 2, 3, 6, 8 and 10.
Compound Virus A B C D E F G H I J K L M N O P Q R
Cell HeLa HeLa HeLa HEL HEL HEL HEL HEL Vero Vero Vero Vero Vero CRFK CRFK MDCK MDCK MDCK
2 EC50
a 0.011 >0.019 >0.019 >0.019 >0.038 >0.038 >0.038 >0.038 >0.038 >0.019 >0.019 >0.019 >0.019 >0.096 >0.096 >0.096 >0.096 >0.096
CC50
b 0.096 0.096 0.096 0.096 0.019 0.019 0.019 0.019 0.019 0.096 0.096 0.096 0.096 >0.096 >0.096 0.046 0.046 0.046
3 EC50 0.147 >0.147 >0.147 >0.147 >0.147 >0.147 >0.147 >0.147 >0.147 >0.147 >0.147 >0.147 >0.147 >0.029 >0.029 >0.147 >0.147 >0.147
CC50 0.147 >0.147 >0.147 >0.147 >0.147 >0.147 >0.147 >0.147 >0.147 >0.147 >0.147 >0.147 >0.147 0.146 0.146 >0.147 >0.147 >0.147
6 EC50 >0.082 >0.082 >0.082 >0.082 >0.082 >0.082 >0.082 >0.082 >0.082 >0.082 >0.082 >0.082 >0.082 >0.03 >0.03 > 0.082 >0.082 >0.082
CC50 >0.082 >0.082 >0.082 >0.082 >0.082 >0.082 >0.082 >0.082 >0.082 >0.082 >0.082 >0.082 >0.082 0.011 0.011 0.082 0.082 0.082
8 EC50 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011
CC50 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011 >0.011
10 EC50 >0.119 >0.119 >0.119 >0.119 >0.119 >0.119 >0.119 >0.119 >0.119 >0.119 >0.119 >0.119 >0.119 0.078 0.105 >0.119 >0.119 >0.119
CC50 >0.119 >0.119 >0.119 >0.119 >0.119 >0.119 >0.119 >0.119 >0.119 >0.119 >0.119 >0.119 >0.119 >0.119 >0.119 >0.119 >0.119 >0.119
Curcumin EC50 >0.01 >0.01 >0.01 >0.01 0.01 0.01 0.01 0.01 >0.01 >0.01 >0.01 >0.01 >0.01 >0.271 >0.271 >0.271 >0.271 >0.271
CC50 0.010 0.010 0.010 0.010 >0.002 >0.002 >0.002 >0.002 0.054 0.054 0.054 0.054 0.054 >0.271 >0.271 >0.092 >0.092 >0.092
D.S-50000 EC50 2 4 0.8 – – – – – >100 >100 20 60 60 – – – – –
CC50 >100 >100 >100 – – – – – >100 >100 >100 >100 >100 – – – – –
(S)-DHPA EC50 146 >250 146 – – – – – >250 >250 >250 >250 >250 – – – – –
CC50 >250 >250 >250 – – – – – >250 >250 >250 >250 >250 – – – – –
Ribavirin EC50 10 30 30 10 50 85 >250 125 95 250 111 >250 50 – – 7 9 9
CC50 >250 >250 >250 >250 >250 >250 >250 >250 >250 >250 >250 >250 >250 – – >100 >100 >100
Brivudine EC50 – – – 0.08 50 2 >250 50 – – – – – – – – – –
CC50 – – – >250 >250 >250 >250 >250 – – – – – – – – – –
HHA EC50 – – – – – – – – – – – – – 12.7 0.8 – – –
CC50 – – – – – – – – – – – – – >100 >100 – – –
UDA EC50 – – – – – – – – – – – – – 1.3 2.9 – – –
CC50 – – – – – – – – – – – – – >100 >100 – – –
Ganciclovir EC50 – – – 0.03 0.03 >100 >100 0.03 – – – – – >100 2.6 – – –
CC50 – – – >100 >100 >100 >100 >100 – – – – – >100 >100 – – –
A, Vesicular Stomatitis virus; B, Coxsackie virus B4; C, Respiratory syncytial virus; D, Herpes simplex virus-1(KOS); E, Herpes simplex virus-2 (G); F, Vaccinia virus; G, Vesicular stomatitis virus; H, Herpes simplex virus-1TK- KOS
ACV; I, Parainfluenza-3 virus; J, Reovirus-1; K, Sindbis virus; L, Coxsakie virus B4; M, Punta toro virus; N, Feline corona virus (FIPV); O, Feline herpes virus; P, Influenza A H1N1 subtype; Q, Influenza AH3N2 subtype; R, Influenza B.
a 50% Effective concentration (mM), or concentration producing 50% inhibition of virus-induced cytopathic effect, as determined by measuring the cell viability with the colorimetric formazan-based MTS assay.
b 50%Cytotoxic concentration (mM), as determined by measuring the cell viability with the colorimetric formazan-based MTS assay.
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Table 3
Measured and predicted log P values of the compounds 2, 3 and curcumin.
Compound Stir-flask method Molinspiration method
P Log P Log P
2 5.50 102 2.74 2.82
3 1.69 108 8.23 9.23
Cur 1.70 102 2.23 2.30
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results were obtained [39]. However, the present work has shown
promise in developing a natural edible substance-curcumin, into
a potential antibacterial and antiviral agent and preparing the
bioconjugates of curcumin has proved beneficial in order to
enhance its cellular delivery.
Further mechanistic studies on compounds 2 and 3 are in
progress against vesicular stomatitis, feline corona and feline
herpes viruses.
5. Experimental section
5.1. Chemistry
Silica gel G for TLC and silica gel (60–120) for column chroma-
tography were obtained from E. Merck India Ltd. Curcumin, folic
acid, dicyclohexylcarbodiimide (DCC), p-nitrophenol (PNP), tri-
fluoro acetic acid (TFA) and 2-chloroethanol were purchased from
Aldrich Chemical Co. USA. The dipeptide, t-boc–N-Trp–Phe–COOH,
was indigenously synthesized. Peptone (std.) was purchased from
Hi Media laboratory Ltd., Mumbai, India. Melting points were
determined by electrothermal apparatus and were uncorrected. UV
measurements were carried out on Hitachi 220S spectrophotom-
eter. 1H NMR spectra were recorded using DRX 300 InstrumentTable 4
Cytotoxicities and Anti-HIV-1 activities of curcumin bioconjugates 2, 3, 6, 8 and 10.
Compound HIV-1
Strains
Exp_nr IC50
a CC50
b SIc
2 IIIB P3.4401 >0.094 ¼0.094 <1
P3.4406 >0.093 ¼0.093 <1
ROD P3.4402 >0.107 ¼0.107 <1
P3.4407 >0.103 ¼0.103 <1
3 IIIB P3.4401 >0.081 ¼0.081 <1
P3.4406 >0.091 ¼0.091 <1
ROD P3.4402 >0.079 ¼0.079 <1
P3.4407 >0.044 ¼0.044
6 IIIB P3.4401 >0.036 ¼0.036 <1
P3.4406 >0.046 ¼0.046
ROD P3.4402 >0.046 ¼0.046 <1
P3.4407 >0.050 ¼0.050
8 IIIB P3.4401 >0.063 ¼0.063 <1
P3.4406 >0.063 ¼0.063
ROD P3.4402 >0.065 ¼0.065 <1
P3.4407 >0.062 ¼0.062
10 IIIB P3.4401 >0.063 ¼0.063 <1
P3.4406 >0.058 ¼0.058
ROD P3.4402 >0.069 ¼0.069 <1
P3.4407 >0.088 ¼0.088
Curcumin IIIB P3.4401 >0.037 ¼0.037 <1
P3.4406 >0.034 ¼0.034
ROD P3.4402 >0.037 ¼0.037 <1
P3.4407 >0.039 ¼0.039
a Compound concentration (mM) required to reduce the viability of mock-infected
cells by 50% as determined by MTT method.
b Compound concentration (mM) required to achieve 50% protection of MT-4 cells
from HIV-1-induced cytopathogenicity as determined by MTT method.
c Selectivity index: CC50/IC50 ratio.with DMSO as solvent using TMS as an internal standard. 13C NMR
spectra were recorded on Varian XL-300 and Bruker AM- 200
spectrometers operating at 75 and 50 MHz, respectively. All
solvents were dried and distilled prior to use.
5.1.1. 1,7-Bis-[(4,4-di-O-tryptophanylphenylalanine)3-methoxy
phenyl]-1,6-heptadiene-3,5-dione (2)
Curcumin (100 mg, 0.27 mmol) and dipeptide (266 mg,
0.59 mmol) were dissolved in dry DCM (10 ml), and stirred for
a few minutes to get a clear solution. Further, DCC (302 mg,
1.47 mmol) and DMAP (66.35 mg) dissolved in DCM (15 ml) were
added to the reaction vessel and stirred the reaction mixture
overnight at room temperature. The completion of the reaction
was assessed by precipitation of dicyclohexylurea (DCU). DCU was
filtered off and the filtrate evaporated to a small volume and par-
titioned between water and ethyl acetate. The organic layer was
evaporated and treated with TFA in DCM (1:1, v/v) to remove t-boc
group from –NH2 function. A positive ninhydrin test indicated the
presence of free amino group. The residue was dissolved in DCM
(30 ml) and this organic fraction was washed consecutively with
5% NaHCO3 solution (20 ml), NaCl (20 ml), H2O (20 ml), dried over
anhydrous Na2SO4, filtered and reduced under vacuum. The title
compound was purified by silica gel column chromatography
using 1–2% CH3OH in CH2Cl2 as a light yellow solid which was
recrystallized from ethanol/water. Yield: 53%; m.p.¼ 204 C,
Rf¼ 0.27 (DCM/MeOH, 9.5:0.5), UV (EtOH) lmax 258, 220 nm. 1H
NMR (DMSO-d6 and D2O) d 2.93 (d, 4H, –CH2-Trp); 3.04 (d, 4H,
–CH2-Ar); 3.74 (s, 6H OCH3, Ar, Cur); 3.95 (m, 2H, CO–CH–NH2);
4.48 (m, 2H, –CH–NH–); 4.59 (s, 2H, C4 of Cur); 6.68 (d, 2H, C2 and
C6 of Cur); 6.80 (d, 2H, Trp); 6.87–6.91 (m, 6H, Ar-Cur); 7.08–7.21
(m, 10H, Ar of Phe); 7.28 (m, 8H, Ar-Trp); 7.53 (d, 2H, C1 and C7,
Cur); 13C NMR (CDCl3): 34.0, 37.0, 51.9, 56.0, 57.0, 62.1, 111.0, 112.1,
112.2, 118.9, 119.6, 120.5, 121.7, 122.3, 122.8, 125.7, 126.6, 126.7,
128.4, 131.6, 136.5, 137.9, 140.2, 140.5, 154.8, 169.7, 196.5, MS m/z
1034 (Mþ). Anal. Calcd for C61H58N6O10: C, 70.79; H, 5.60; N, 8.12.
Found: C, 70.78; H, 5.65; N, 8.11.
5.1.2. 1,7-Bis-[(4,4-di-O-decanoyl)3-methoxy phenyl]-1,6-
heptadiene-3,5-dione (3)
To curcumin (100 mg, 0.27 mmol) dissolved in dry pyridine
(10 ml), added decanoyl chloride (0.12 ml, 0.61 mmol) and DMAP
(66.35 mg) under cooled condition and stirred the reaction mixture
overnight at room temperature. After completion of the reaction, as
indicated by TLC, added chilled water (5 ml) and stirred for 10 min.
Further, the volume of reaction mixture was reduced, the residue
dissolved in EtOAc (20 ml), washed with water and dried up. The
title compound was purified by column chromatography using
ethyl acetate (1.5–2%) in hexane as a dark red solid which was
recrystallized from EtOAc and Hexane. Yield: 56%; m.p.¼ 225 C,
Rf¼ 0.35 (EtOAc:Hexane, 3.5:6.5), UV (EtOH) lmax 250, 228, nm. 1H
NMR (DMSO-d6 and D2O); d 0.96 (t, 6H, CH3 of decanoic acid); 1.28
(m, 20H, –CH2, of decanoic acid); 1.32 (m, 4H, –CH2 of decanoic
acid); 1.54 (m, 4H, –CH2 of decanoic acid); 2.21 (t, 4H, –CH2 of
decanoic acid); 3.72 (s, 6H OCH3, Ar of Cur); 4.58 (s, 2H, C4 of Cur);
6.67 (d, 2H, C2 and C6 of Cur); 6.78–6.91 (m, 6H, Ar-Cur); 7.54 (d,
2H, C1 and C7 of Cur); 13C NMR (CDCl3): d 14.0, 25.4, 29.7, 30.0, 30.3,
33.2, 32.5, 51.9, 56.0, 112.2, 118.9, 123.1, 122.3, 132.7, 137.9, 140.5,
154.8, 169.0, 196.5, MS m/z 676 (Mþ). Anal. Calcd for C41H56O8: C,
72.75; H, 8.28 found: C, 72.78; H, 8.34.
5.1.3. 1,7-Bis-[(4,4-di-O-pamitoyl)3-methoxy phenyl]-1,6-
heptadiene-3,5-dione (4)
To curcumin (100 mg, 0.27 mmol) dissolved in dry pyridine
(10 ml), added pamitoyl chloride (0.18 ml, 0.62 mmol) and DMAP
(66.35 mg) under cooled condition and stirred the reaction mixture
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on to chilled water (5 ml) and worked up as in the case of
compound 3. The title compound was obtained as a yellow powder,
which was recrystallized from a mixture of ethanol and water.
Yield: 44%; m.p.¼100 C, Rf¼ 0.69 (EtOAc: Hexane, 3.0:7.0). UV
(EtOH) lmax 260, 245, nm.
1H NMR (DMSO-d6 and D2O) d 0.97 (t, 6H,
CH3 of palmitic acid); 1.29 (m, 44H, –CH2 of palmitic acid); 1.36 (m,
4H, –CH2 of palmitic acid); 1.58 (m, 4H, –CH2 of palmitic acid); 2.25
(t, 4H, –CH2 of palmitic acid); 3.73 (s, 6H OCH3, Ar of Cur); 4.59 (s,
2H, C4 of Cur); 6.68 (d, 2H, C2 and C6 of Cur); 6.76–6.93 (m, 6H, Ar
of Cur); 7.56 (d, 2H, C1 and C7 of Cur); 13C NMR (CDCl3): d 196.5,
169.0, 154.8, 140.5, 137.9, 132.7, 126.6, 122.3, 118.9, 112.2, 56.0, 36.0,
33.2, 32.5, 32.0, 30.3, 30.0, 29.7, 25.4, 23, 14.0, MS m/z 844 (Mþ).
Anal. Calcd for C53H80O8: C, 75.20; H, 9.46 found: C, 75.32; H, 9.54.
5.1.4. p-Nitro phenyl ester of folic acid (5)
To a stirred solution of folic acid (2 g, 5 mmol) in anhydrous
ethyl acetate (10 ml), added dropwise p-nitrophenol (0.834 g,
6 mmol) dissolved in ethyl acetate (10 ml). After 15 min, pyridine
and triethylamine (1 ml each) were added to make it more basic,
stirred for 15 min and further added DCC (2.579 g, 12.5 mmol). The
reaction mixture was stirred for 2.5 h and monitored on TLC. The
completion of the reaction was assessed by total consumption of
the starting material.
5.1.5. 1,7-Bis-[(4,4 -di-O-bis-(g,g)-folyl)3-methoxy phenyl]-1,6-
heptadiene-3,5-dione (6)
Curcumin (94 mg, 0.25 mmol) dissolved in dry pyridine (5 ml)
was added dropwise to activated folate ester 5 (323 mg,
0.57 mmol), stirred for 15 min and TEA (0.5 ml), DCC (292 mg,
1.42 mmol) and DMAP (61 mg) were further added. The reaction
mixturewas stirred for 5 h andmonitored onTLC. The precipitate of
DCU started to appear after 30 min. At the end of the reaction, DCU
was filtered off, the filtrate evaporated and the residue dissolved in
EtOAc (20 ml). This organic fractionwas washed consecutively with
5% NaHCO3 solution (20 ml) (to neutralize the residual acid and to
separate excess amount of PNP), NaCl (20 ml), H2O (20 ml), dried
over anhydrous Na2SO4, filtered and reduced under vacuum. The
title compound was purified by silica gel column chromatography
using ethyl acetate (1.5–2%) in hexane as eluant and recrystallized
from ethanol/water. Yield: 48%; m.p.¼ 238 C, Rf¼ 0.6 (EtOA-
c:Hexane, 3.5:6.5), UV(EtOAc) lmax 280, 300 nm.
1H NMR (DMSO-d6
and D2O); d 2.09 (m, 4H, C21, FA); 2.23 (m, 4H, C22, FA); 3.73 (s, 6H
OCH3, Ar, Cur); 4.32 (s, 4H, C9 H, FA); 4.46 (m, 2H, C19, FA); 4.58 (s,
2H, C4, Cur); 6.61 (d, 4H, C12 and C16, Ar, FA); 6.79 (d, 2H, C2 and C6,
Cur); 6.89–6.91 (m, 6H, Ar-Cur); 7.54 (d, 2H, C1 and C7, Cur); 7.73 (d,
4H, C13 and C15, Ar, FA); 8.8 (s, 2H, C7, pyrazine, FA); 13C NMR
(CDCl3): d 26.3, 27.5, 51.9, 56.0, 56.7, 57.4, 112.2, 112.4, 118.9, 121.9,
122.3, 126.6, 128.1, 132.7, 137.9, 138.1, 140.5, 146.9, 148.4, 150.8,
154.8, 161.2, 163, 169.0, 170,196.5, MSm/z 1214 (Mþ). Anal. Calcd for
C59H54N14 O16: C, 58.31; H, 4.44; N,16.14 found: C, 58.35; H, 4.48; N,
16.10.
5.1.6. 1,7-Bis-[(4-hydroxy-3-methoxyphenyl)]-1,6-heptadiene-C4-
ethyl-O-folyl-3,5-dione (8)
To curcumin (184 mg, 0.5 mmol) dissolved in dry pyridine
(10 ml), added KOH (67.2 mg, 1.2 mmol), cooled the solution and
further added benzoyl chloride (1.4 ml, 1.2 mmol) dropwise with
constant stirring which continued at ambient temperature for
another 2 h. The completion of the reaction was assessed on TLC.
The volume of the reaction mixture was reduced to half and poured
on to crushed ice and the product was extracted with EtOAc. The
organic phase was dried over anhydrous Na2SO4, concentrated and
the product was purified by silica gel column chromatography using
2% EtOAc/Hexane. This di-O-benzoyl curcumin (200 mg,0.34 mmol) was dissolved in ethanol (7 ml) and NaOEt was added
dropwise at room temperature over 20 min and the reaction
mixture was stirred for another 30 min. The sodium salt was
concentrated under vacuum, washed thoroughly with ethanol,
dissolved in pyridine (5 ml) and furthermixedwith 2-chloroethanol
(0.067 ml, 1 mmol). The reaction mixture was stirred at room
temperature for 6 h. After completion of the reaction, the mixture
was poured on to crushed ice and extracted thoroughly with EtOAc,
dried over anhydrous Na2SO4 and concentrated to get the inter-
mediate compound 7 (183 mg, 0.29 mmol). The compound 7, dis-
solved in dry pyridine (5 ml), was added dropwise to the activated
folate ester 5 (286 mg, 0.51 mmol) and stirred the reaction mixture
for 15 min. TEA (0.5 ml), DCC (257 mg, 1.25 mmol) and DMAP
(61 mg) were further added. The reaction mixture was stirred for
5 h and the reaction was monitored on TLC.
The precipitate of DCU started to appear after 30 min. After the
completion of the reaction, DCU was filtered off and the filtrate was
evaporated to dryness. After deprotection of both phenolic
hydroxyl functions on curcumin with NH3–pyridine (9:1v/v) at
55 C, ammonia was removed using water pump, the solvent
evaporated and the residue dissolved in EtOAc (20 ml). The product
was purified by silica gel column chromatography using ethyl
acetate (1–2%) in hexane as eluant. The title compound was
recrystallized from ethanol/water as light brown solid. Yield: 45%;
m.p.¼ 210 C, Rf¼ 0.57 (EtOAc:Hexane, 3.5:6.5), UV(EtOAc) lmax
245, 275, 300 nm. 1H NMR (DMSO-d6 and D2O); d 1.75 (m, 2H, C2,
ethyl), 2.21 (m, 2H, C21, FA); 2.25 (m, 2H, C22, FA); 3.21 (t, 1H, C4,
Cur); 3.73 (s, 6H OCH3, Ar, Cur); 4.08 (t, 2H, C1, ethyl), 4.32 (s, 2H, C9
H, FA); 4.46 (m, 1H, C19, FA); 6.54 (d, 2H, C12 and C16 Ar, FA); 6.56
(d, 2H, C2 and C6, Cur); 6.57–6.69 (m, 6H, Ar-Cur); 7.54 (d, 2H, C1
and C7, Cur); 7.73 (d, 2H, C13 and C15, Ar, FA); 8.8 (s, 1H, C7, pyr-
azine, FA); 13C NMR (CDCl3): d 21.8, 26.3, 27.9, 56.7, 60.7, 63.5, 112.4,
113.2, 116.6, 119.9, 118.9, 121.9, 122.3, 126.6, 128.1, 128.5, 128.9, 138.1,
140.5, 142.1, 146.9, 148.4, 149.1, 150.8, 161.2, 167.9, 177.0, 172.0, 197.6,
MSm/z 835 (Mþ). Anal. Calcd for C42H41N7O12: C, 60.35; H, 4.91; N,
11.73 found: C, 60.38; H, 4.94; N, 11.77.
5.1.7. 1-(4-Hydroxy-3-methoxyphenyl)-7-(4-O-ethyl-O-folyl-3-
methoxyphenyl)-1,6-heptadiene-3,5-dione (10)
To curcumin (184 mg, 0.5 mmol) dissolved in aq NaOH (5%,
10 ml), added 2-chloroethanol (0.05 ml, 0.75 mmol) and stirred the
reaction mixture for 7 h. The reaction mixture was extracted with
EtOAc. The organic extract was concentrated under vacuum,
washed with 5% NaHCO3, dried over anhydrous Na2SO4, evaporated
and crystallized with ethanol and water to get the intermediate
compound 9. Yield (100 mg, 0.24 mmol, 48%).
Compound 9 (100 mg, 0.24 mmol), dissolved in dry pyridine
(6 ml), was added dropwise to the activated ester 5 (157 mg,
0.28 mmol), stirred the reaction mixture for 20 min and TEA
(0.5 ml), DCC (123 mg, 0.6 mmol) and DMAP (32 mg) were further
added.
The reaction mixture was stirred for 5 h and the reaction was
monitored on TLC. DCU was filtered off and the product was
obtained following the usual work up procedure and purification
by silica gel column chromatography using ethyl acetate (2%) in
hexane as eluant as a red solid which was recrystallized from EtOAc
and hexane. Yield: 26%; m.p.¼168–170 C, Rf¼ 0.53 (EtOAc:
Hexane 6.5:3.5). UV (EtOH) lmax 270, 290, nm.
1H NMR (DMSO-d6
and D2O); d 2.23 (m, 2H, C21, FA); 2.25 (m, 2H, C22, FA); 3.23 (t, 1H,
C4, Cur); 3.75 (s, 6H OCH3, Ar, Cur); 4.22 (m, 2H, C2, ethyl), 4.34 (s,
2H, C9, FA); 4.50 (m, 2H, C1, ethyl), 4.45 (m,1H, C19, FA); 6.60 (d, 2H,
C12 and C16, Ar, FA); 6.68 (d, 2H, C2 and C6, Cur); 6.70–6.75 (m, 6H,
Ar-Cur); 7.55 (d, 2H, C1 and C7, H Cur); 7.72 (d, 2H, C13 and C15, Ar,
FA); 8.6 (s, 1H, C7 H, pyrazine, FA); 13C NMR (CDCl3): 26.3, 27.9, 51.9,
56.3, 56.7, 57.4, 67, 72.2, 112.4, 113.2, 115.1, 116.6, 119.1, 119.9, 126.6,
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150.8, 161.2, 163, 167.9, 170.0, 172.0, 177.0, 196.5, MS m/z 835 (Mþ).
Anal. Calcd for C42H41N7O12: C, 60.35; H, 4.91; N, 11.73 found: C,
60.34; H, 4.94; N, 11.75.5.2. Pharmacology
5.2.1. Antibacterial assay
The in vitro antibacterial activity of each curcumin bioconjugate
against Gram-positive cocci (S. viridans) and Gram-negative bacilli
(E. coli, K. pneumoniae, P. mirabeilis) was evaluated by microdilution
broth susceptibility test method. The bacterial strains were isolated
from clinical patients following the standard protocols [38].
The antibacterial activities of curcumin bioconjugates, 2, 3, 4, 6
and 8were compared with that of curcumin. The stock solutions of
the conjugates along with curcumin prepared in water/DMSO to
ensure complete solubilization were doubly diluted to the
concentrations 1000 mg; 500 mg, 250 mg, 125 mg and 65.5 mg to
which peptone-water (1 ml) was added. The fresh culture of
aforementioned strains was prepared and a standardized bacterial
suspension (100 ml) of 0.5 McFarland turbidity was added to each
dilution. Suitable solvent control (DMSO), positive growth control
and standard control were also run simultaneously [39].
The tubes bearing different concentrations of the compounds
and control tubes were incubated at 37 C for 24 h. After incuba-
tion, antibacterial activity of molecules in the tube was detected by
lack of turbidity which indicated the inhibition of bacterial growth.
The concentration in the tube with highest dilution showing no
turbidity has been reported as MIC. Each test was performed in
triplicate and the MICs reported represent the result of at least two
repetitions.
5.2.2. Antiviral assay
The antiviral assay was based on inhibition of virus-induced
cytopathogenicity in various cell cultures as described previously
[39–43]. The assays were performed against various viruses, viz.
herpes simplex virus type 1 (strain KOS), herpes simplex virus type
2 (strain G), cytomegalovirus (CMV) from sindbis virus (SV), para-
influenza virus type 3 (PIV-3) and reovirus type-3, vesicular stro-
matitis virus (VSV), coxsackie virus (Coxs V), respiratory syncytial
virus (RSV) using CRFK, HEL, HeLa and Vero cell lines and HIV-1 (IIIB
and ROD strains) in MT-4 cells using MTT method.
5.2.2.1. Virus cytopathogenicity. The confluent cell cultures were
prepared in microdilution trays and inoculated with 100 CCID50 (1
CCID50 corresponding to the virus stock dilution that proved
infective for 50% of cell cultures). After 1 h of virus adsorption to the
cells at 37 C, the residual virus was replaced by cell culture
medium (Eagle minimum essential medium supplemented with 3%
fetal calf serum and antibiotics) and various concentrations of the
test compounds 2, 3, 6, 8 and 10. Virus cytopathogenicity was
recorded as it reached completion in the untreated virus-infected
cell cultures, i.e., at 1–2 days for vesicular stomatitis virus; 2 days
for coxasackie; 2–3 days for vaccinia, herpes simplex type 1 and 2
and sindbis, 4 days for respiratory syncytial virus and 6–7 days for
reo and parainfluenza viruses [44,45].
The antiviral activity of the compound is expressed as the EC50
or the concentration (mM) required to inhibit virus-induced cyto-
pathogenicity by 50%. The viruses used are either DNA or (þ)/()
stranded RNA viruses.
5.2.2.2. Cytotoxicity. The cytotoxicity of the test compounds 2, 3, 6,
8 and 10was assessed on the basis of two parameters: (i) alteration
of normal cell morphology, and (ii) inhibition of macromolecule(DNA, RNA and protein) synthesis. Cytotoxicity (CC50) of the
compounds was examined by trypan blue exclusion test.
To evaluate cytotoxicity, uninfected confluent cell cultures
treated with various concentrations of the test compounds, were
incubated in parallel with virus-infected cell cultures prepared in
plastic trays containing 24 wells (16 mm diameter; Falcon plastics).
After 2 days of incubation at 37 C in a CO2 incubator, when the cell
cultures were confluent, culture medium was removed from each
well and 1 ml of maintenance medium containing serial concen-
trations of the test compounds was added. For the cell control, 1 ml
of maintenance medium without compound was added. All
cultures were incubated at 37 C, and after 2 and 7 days of incu-
bation, compounds were withdrawn and the viability of the cells
was determined by the trypan blue exclusion method.
5.2.3. Ant-HIV assay
Antiviral screening against HIV – 1 (IIIB and ROD strains) was
monitored by the efficiency of drug compounds to inhibit syncytia
formation after HIV infection of MT – 4 cells following the MTT
method [45–47]. The activity of the compounds against HIV-1 was
monitored by inhibition of HIV-1-induced cytopathogenicity inMT-
4 cells. Briefly, MT-4 cells (3104 cells per well in 96 well plate)
were cultured in microdilution trays in the presence of various
concentrations of the test compounds added immediately after
infectionwith 50% cell culture infective doses of HIV-1. After 5 days
of incubation at 37 C, the number of viable cells was determined
by the MTT (30-[4,5-dimethylthiazole-2-yl]-2,5-diphenylte-
trazolium bromide) method.
5.2.4. Determination of log P value
The partition coefficients of bioconjugates 2 and 3 along with
curcumin were determined by the stir-flask method [37]. Octanol
and 0.1 NaOH solution were mutually saturated and both phases
were separated by centrifugation (5000 rpm, 10 min). A stock
solution of each molecule (4  103 M) was prepared using octa-
nol-saturated NaOH solution. A part of these solutions were kept
aside for UV measurement. Further, NaOH-saturated octanol was
added at various volume ratios to other part of the stock solution.
Then the two-phase mixtures were intensively stirred for 4 h at
constant temperature (25 C). The absorbance of the aqueous
solutions was measured by UV–vis spectrophotometer at lmax
258 nm for compound 2 and lmax 250 nm for compound 3 and
223 nm for curcumin. The P value was calculated as follows:
P ¼ A0  A1
A1
 Vw
V0
where A0 and A1 represent the absorbance of the molecule in the
aqueous phase before and after partitioning, Vw and V0 are the
water and octanol volumes, respectively. Log P values are an
average of three measurements.
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